Biomarker ID | 96 |
PMID | 15870707 |
Year | 2005 |
Biomarker | E-cadherin |
Biomarker Basis | Concentration Based (μg/L) |
Biomolecule | Protein |
Source | Serum |
Subjects | Humans |
Regulation | Iincreased risk of late biochemical failure with high expression |
Odds Ratio/Hazard Ratio/Relative Risk | RR: 55.1 |
Effect on Pathways | Pathways include: 1. Integrin cell surface interactions 2. Nuclear beta-catenin signaling and target gene transcription regulation 3. Cell junction organization 4. Adherens junction cell adhesion 5. Neural crest differentiation |
Experiment | Biochemical Faliure Vs No Biochemical Faliure |
Type of Biomarker | Prognostic |
Cohort | 109 patients with localised prostate cancer (Loc PCA) and no biochemical failure, and 21 cases with localised PCA and biochemical failure after surgery. |
Senstivity | NA |
Specificity | NA |
AUC | NA |
Accuracy | NA |
Level Of Significance | p<0.05 |
Method Used | Enzyme Immunoassay (EIA) |
Clinical | No |
Remarks | cutoff expression level 7.9 μg/l |
Clinical Trial Number | NA |
Degree Of Validity | Not validated on independent patient dataset |
Technical Name | CDH1 |